[New developments in medical mycology].
Not only have the systemic mycoses clearly increased in number but also mycoses of the skin are more common than presumed in the past. Today onychomycosis is found in up to 10% of human beings. Onychomycosis can compromise quality of life markedly. Common tinea pedis is one of the most important risk factors for erysipelas of the lower legs. The clinical presentation of oral candidosis in HIV-infected patients is changing; Candida dubliniensis has been identified as another important causative microorganism. Onychomycosis today in most cases can be cured using terbinafine or itraconazole. When choosing the ideal drug in a given case, both the benefit risk ratio and the benefit cost ratio have to be taken into account. Liposomally encapsulated amphotericin B represents a major breakthrough in the treatment of systemic mycoses or fever of unknown origin. The same applies to liposomally encapsulated econazole with respect to tinea pedis. In regard to the pathogenesis of Candida infections the family of secreted aspartic proteinases plays a major role as a virulence factor and possible future target for antimycotic treatment.
Korting
H C
HC
Klinik und Poliklinik für Dermatologie und Allergologie, Ludwig-Maximilians-Universität München, Frauenlobstrasse 9-11, 80337 München.
Schaller
M
M
D017088:AIDS-Related Opportunistic Infections / Q000175:diagnosis / Q000188:drug therapy; D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D000935:Antifungal Agents / Q000008:administration & dosage / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use; D016282:Aspartic Acid Endopeptidases / Q000032:analysis; D001365:Axilla; D002176:Candida albicans / Q000187:drug effects / Q000201:enzymology / Q000302:isolation & purification; D002177:Candidiasis / Q000175:diagnosis / Q000188:drug therapy; D002179:Candidiasis, Cutaneous / Q000175:diagnosis / Q000188:drug therapy; D002180:Candidiasis, Oral / Q000175:diagnosis / Q000188:drug therapy; D002181:Candidiasis, Vulvovaginal / Q000175:diagnosis / Q000188:drug therapy; D016022:Case-Control Studies; D002648:Child; D002986:Clinical Trials as Topic; D003881:Dermatomycoses / Q000175:diagnosis / Q000188:drug therapy; D005260:Female; D006801:Humans; D008081:Liposomes; D016253:Microscopy, Immunoelectron; D015337:Multicenter Studies as Topic; D015999:Multivariate Analysis; D009281:Naphthalenes / Q000008:administration & dosage / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use; D014009:Onychomycosis / Q000175:diagnosis / Q000188:drug therapy; D017410:Practice Guidelines as Topic; D011446:Prospective Studies; D012307:Risk Factors; D000077291:Terbinafine; D014005:Tinea / Q000175:diagnosis / Q000188:drug therapy; D014008:Tinea Pedis / Q000175:diagnosis / Q000188:drug therapy; D014249:Trichophyton / Q000187:drug effects / Q000302:isolation & purification
D000935:Antifungal Agents; D008081:Liposomes; D009281:Naphthalenes; D000666:Amphotericin B; D016282:Aspartic Acid Endopeptidases; D000077291:Terbinafine